Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial

RATIONALE & OBJECTIVE: In kidney transplant recipients (KTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)–based regimens. Our objective was to compare the calculated CV risk betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Bredewold, Obbo W., Chan, Joe, Svensson, My, Bruchfeld, Annette, de Fijter, Johan W., Furuland, Hans, Grinyo, Josep M., Hartmann, Anders, Holdaas, Hallvard, Hellberg, Olof, Jardine, Alan, Mjörnstedt, Lars, Skov, Karin, Smerud, Knut T., Soveri, Inga, Sørensen, Søren S., Zonneveld, Anton-Jan van, Fellström, Bengt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803830/
https://www.ncbi.nlm.nih.gov/pubmed/36593877
http://dx.doi.org/10.1016/j.xkme.2022.100574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803830/
https://www.ncbi.nlm.nih.gov/pubmed/36593877
http://dx.doi.org/10.1016/j.xkme.2022.100574

Ejemplares similares